The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Jordi Remon

Consulting or Advisory Role: Pfizer, Bristol Myers Squibb, MSD Oncology, AstraZeneca, OSE Immunotherapeutics, Janssen Oncology, Genmab, Boehringer Ingelheim, Sanofi, Roche/Genentech

Travel, Accommodations, Expenses: Roche/Genentech, Inivata, OSE Immunotherapeutics, AstraZeneca

Lizza E.L. Hendriks

Consulting or Advisory Role: Bristol Myers Squibb (Inst), Roche/Genentech (Inst), Lilly (Inst), Pfizer (Inst), Takeda (Inst), Boehringer Ingelheim (Inst), AstraZeneca (Inst), MSD (Inst), Amgen (Inst), Janssen (Inst), Novartis (Inst)

Speakers' Bureau: MSD (Inst), Medtalks, Benecke, high5oncology (Inst), VJOncology, Bayer (Inst), Lilly (Inst), AstraZeneca (Inst), Takeda (Inst)

Research Funding: Roche/Genentech (Inst), AstraZeneca (Inst), Boehringer Ingelheim (Inst), Takeda (Inst), BeiGene (Inst)

Travel, Accommodations, Expenses: Roche/Genentech, MSD

Other Relationship: AstraZeneca, Roche/Genentech (Inst), GlaxoSmithKline (Inst), Novartis (Inst), Merck Serono (Inst), Roche/Genentech (Inst), Takeda (Inst), BluPrint Oncology (Inst), Mirati Therapeutics (Inst), Janssen Oncology (Inst), AbbVie (Inst), Gilead Sciences (Inst)

Martin Reck

Consulting or Advisory Role: Lilly, MSD Oncology, Merck Serono, Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, Roche/Genentech, AbbVie, Amgen, Mirati Therapeutics, Samsung Bioepis, Sanofi/Regeneron, Daiichi Sankyo Europe GmbH

Speakers' Bureau: Roche/Genentech, Lilly, MSD Oncology, Merck Serono, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Pfizer, Novartis, Amgen, Mirati Therapeutics, Sanofi/Aventis

No other potential conflicts of interest were reported.